Athersys, Inc.
Index- P/E- EPS (ttm)-0.35 Insider Own0.60% Shs Outstand244.20M Perf Week-5.49%
Market Cap67.46M Forward P/E- EPS next Y-0.23 Insider Trans8.85% Shs Float238.11M Perf Month1.89%
Income-82.70M PEG- EPS next Q-0.06 Inst Own22.10% Short Float11.76% Perf Quarter-56.40%
Sales8.40M P/S8.03 EPS this Y7.70% Inst Trans2.61% Short Ratio3.80 Perf Half Y-76.63%
Book/sh0.00 P/B- EPS next Y466.70% ROA-132.00% Target Price1.62 Perf Year-82.92%
Cash/sh0.08 P/C3.09 EPS next 5Y- ROE-429.20% 52W Range0.18 - 1.81 Perf YTD-72.56%
Dividend- P/FCF- EPS past 5Y-16.50% ROI- 52W High-86.33% Beta-1.30
Dividend %- Quick Ratio1.00 Sales past 5Y-20.50% Gross Margin- 52W Low37.50% ATR0.04
Employees104 Current Ratio1.00 Sales Q/Q-43.10% Oper. Margin- RSI (14)39.98 Volatility12.65% 18.48%
OptionableYes Debt/Eq0.00 EPS Q/Q28.40% Profit Margin- Rel Volume0.36 Prev Close0.25
ShortableYes LT Debt/Eq0.00 EarningsMay 06 BMO Payout- Avg Volume7.37M Price0.25
Recom2.20 SMA20-17.31% SMA50-37.04% SMA200-70.18% Volume247,312 Change-0.08%
Nov-19-21Downgrade BofA Securities Buy → Neutral
Jun-25-20Initiated BofA/Merrill Buy $5
Aug-26-19Initiated Dawson James Buy $11
Feb-13-18Reiterated Maxim Group Buy $12 → $6
Aug-10-17Reiterated Maxim Group Buy $9 → $12
Feb-07-17Initiated Needham Buy $7
Mar-11-16Reiterated Maxim Group Buy $5 → $10
Jul-09-15Downgrade Piper Jaffray Overweight → Neutral
Jan-23-15Reiterated Maxim Group Buy $7 → $9
Apr-28-14Reiterated Maxim Group Buy $10 → $7
Dec-19-13Reiterated Maxim Group Buy $6 → $10
Oct-05-12Reiterated Maxim Group Buy $3 → $6
May-31-12Initiated Maxim Group Buy $3
Sep-13-10Reiterated WBB Securities Strong Buy $8 → $9
Jul-30-10Upgrade WBB Securities Buy → Strong Buy $8
Apr-12-10Initiated Brean Murray Buy $8
Nov-11-08Reiterated Leerink Swann Outperform $8 → $4
Sep-17-08Initiated Leerink Swann Outperform $8
Aug-01-08Initiated Canaccord Adams Buy $6
Jun-19-08Initiated Lazard Capital Buy $7
Jul-05-22 08:30AM  
Jun-28-22 02:07PM  
Jun-21-22 06:00AM  
Jun-17-22 02:55PM  
Jun-15-22 08:43AM  
Jun-09-22 01:02PM  
Jun-08-22 02:45PM  
Jun-02-22 06:35PM  
May-23-22 03:32PM  
May-20-22 10:21AM  
May-13-22 08:00AM  
May-11-22 06:35AM  
May-06-22 08:00AM  
May-02-22 09:00AM  
Apr-29-22 09:00AM  
Apr-04-22 03:40PM  
Apr-01-22 04:46PM  
Mar-28-22 12:19PM  
Mar-16-22 06:23PM  
Mar-15-22 04:05PM  
Mar-10-22 11:50AM  
Mar-08-22 10:56AM  
Feb-23-22 09:40AM  
Feb-18-22 03:21PM  
Feb-17-22 04:30PM  
Feb-15-22 08:00AM  
Feb-04-22 09:40AM  
Feb-03-22 01:38PM  
Jan-28-22 09:38AM  
Jan-26-22 08:00AM  
Jan-21-22 12:54PM  
Dec-29-21 08:39AM  
Nov-30-21 06:00AM  
Nov-24-21 12:00PM  
Nov-22-21 11:54AM  
Nov-16-21 01:30AM  
Nov-15-21 04:05PM  
Nov-12-21 07:40AM  
Nov-08-21 07:00AM  
Oct-18-21 10:07AM  
Sep-28-21 07:00AM  
Sep-24-21 06:43AM  
Sep-22-21 08:16AM  
Aug-16-21 09:33AM  
Aug-10-21 09:17AM  
Aug-09-21 04:05PM  
Aug-06-21 06:12AM  
Aug-05-21 05:57PM  
Jul-29-21 03:02PM  
Jul-13-21 10:30AM  
Jun-30-21 06:00AM  
Jun-25-21 01:24AM  
May-07-21 01:01AM  
May-06-21 04:05PM  
Apr-28-21 01:00PM  
Apr-21-21 12:00PM  
Apr-13-21 07:00AM  
Apr-01-21 07:00AM  
Mar-31-21 03:45PM  
Mar-27-21 03:45AM  
Mar-25-21 09:00PM  
Mar-02-21 07:00AM  
Feb-16-21 07:50AM  
Jan-28-21 08:04AM  
Jan-08-21 08:32AM  
Dec-21-20 03:41PM  
Dec-02-20 03:48PM  
Nov-16-20 06:00AM  
Nov-14-20 07:39AM  
Nov-11-20 06:00PM  
Nov-09-20 04:05PM  
Nov-05-20 06:05AM  
Oct-08-20 01:17PM  
Sep-29-20 08:53AM  
Sep-24-20 01:29PM  
Sep-23-20 09:57AM  
Aug-11-20 02:00AM  
Aug-10-20 04:00PM  
Aug-07-20 08:58AM  
Jul-20-20 02:00PM  
Jun-25-20 10:10AM  
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Camardo Daniel A.CEOMar 17Buy0.77132,800102,256132,800Mar 17 11:09 AM
Lehmann William JRInterim CEO, President, COODec 15Option Exercise1.285,0006,400481,287Dec 15 11:11 AM
Kola IsmailDirectorNov 19Buy0.9685,00081,702100,000Nov 19 01:34 PM
Macleod ivorChief Financial OfficerNov 17Buy1.1815,00017,706146,583Nov 17 11:16 AM
Lehmann William JRInterim CEO, President, COOOct 28Option Exercise1.285,0006,400476,287Oct 28 10:25 AM
Lehmann William JRInterim CEO, President, COOSep 20Sale1.4130,00042,300471,287Sep 21 05:01 PM
Harrington John JExec Vice Pres and CSOSep 16Sale1.455,0007,250742,941Sep 17 07:58 PM
Harrington John JExec Vice Pres and CSOSep 15Sale1.4621,05030,733747,941Sep 17 07:58 PM